Stock Price & Analysis

Buy MDGL stock as strong analyst ratings and positive earnings momentum outweigh insider selling concerns. Hold or accumulate on dips given the 24.4% upside potential indicated by analyst price targets.

The predicted price for MDGL stock in 2025 is approximately $416, based on analyst consensus and positive gross profit growth. However, caution is advised due to the company's net loss and recent insider selling activity.

The S1 support level for MDGL Stock is $307.2 ,The R1 resistant level for MDGL Stock is $345.73.

As of the end of day on 2025-03-14, the price of MDGL Stock was $343.57.

The target price for MDGL Stock according to analyst rating is 413.87, with the highest price target at 539.00 and the lowest at 239.00. Analysts have a Strong Buy rating on MDGL Stock overall.

The market cap of MDGL is $7.1B.

Analysis and Insights

Valuation Metrics:

MDGL's valuation metrics indicate a mixed outlook. The stock currently trades at $324.7, with analyst price targets suggesting a potential 24.4% upside. However, the company's negative net income and ROE raise concerns about profitability.

Financial Health:

• Revenue Growth: MDGL's revenue has grown significantly in 2024, from $0 in Q1 to $103.32 million in Q4.
• Net Loss: The company reported net losses in all quarters of 2024, with a significant loss of $1.475 billion in Q1.
• Gross Margin: High gross margins of 95.66% to 96.67% indicate strong cost management.
• Current Ratio: A healthy current ratio of 5.98 to 9.39 suggests good liquidity.
• Debt-to-Equity Ratio: Negative values may indicate high liabilities or negative equity.

Market Sentiment:

• Analyst Ratings: A Strong Buy consensus with price targets ranging from $400 to $415.
• Insider Activity: Recent insider sales, but institutional investors show mixed sentiment.

Technical Analysis:

The stock is trading below its Fibonacci pivot level of $336.13, with RSI at 47.78, indicating potential undervaluation.

Conclusion:

MDGL's high revenue growth and strong gross margins justify its current valuation despite net losses. Analyst optimism and potential upside suggest the stock is not overvalued.

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Price Prediction for MDGL Stock in 2030

Based on current trends and analyst expectations, MDGL stock is predicted to reach $550 by 2030, driven by the success of Rezdiffra and strong growth prospects in the healthcare sector. The stock has shown significant volatility but maintains a bullish outlook due to positive clinical trial results and analyst upgrades.

MDGL has a total of 376 employees.